Want to see SE:HUM full AI Analyst Report?
Top Page
Humana AB
(HUM)
Select Model
Select Model
Rating:71Outperform
Price Target:
kr78.00
▲(26.01% Upside)
Action:Upgraded
Date:07/23/26
The score is driven mainly by strong financial performance (notably accelerating revenue and robust free cash flow) tempered by meaningful leverage and thin net margins. Technicals add support with an uptrend above major moving averages and positive MACD, while valuation is reasonable with a mid-level P/E and moderate dividend yield.
Positive Factors
Strong TTM revenue acceleration
The sharp TTM top-line acceleration indicates renewed service demand, higher activity or improved mix. If sustained, this can broaden the operating base and improve the company’s ability to absorb fixed staffing and facility costs.
Negative Factors
Material leverage limits flexibility
Debt remains a meaningful constraint for a labor-intensive care provider with regulated reimbursement. Limited operating-cash-flow coverage of total debt could restrict investment capacity and increase sensitivity to operating setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong TTM revenue acceleration
The sharp TTM top-line acceleration indicates renewed service demand, higher activity or improved mix. If sustained, this can broaden the operating base and improve the company’s ability to absorb fixed staffing and facility costs.
Read all positive factors
Humana AB (HUM) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr3.40B
Dividend Yield1.88%
Average Volume (3M)120.62K
Price to Earnings (P/E)20.1
Beta (1Y)0.66
Revenue Growth-3.48%
EPS Growth-14.02%
CountrySE
Employees11,127
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)3.53
Shares Outstanding48,039,394
10 Day Avg. Volume123,370
30 Day Avg. Volume120,620
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.81
Price to Sales (P/S)0.25
P/FCF Ratio3.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.47
Revenue Forecast (FY)kr10.22B
Humana AB Business Overview & Revenue Model
Company Description
Humana AB (publ), founded in 2001 and headquartered in Stockholm, Sweden, offers a wide range of individual and family care services across Sweden, Finland, Norway, and Denmark, serving both children and adults. The company's operations are divide...
How the Company Makes Money
Humana AB primarily makes money by delivering care services that are reimbursed through public-sector funding mechanisms (and, where applicable, municipal/regional contracts) and paid according to regulated or contracted rates. Key revenue streams...
Humana AB Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
58
Neutral
Cash Flow
76
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.03B | 10.01B | 10.29B | 9.65B | 9.20B | 8.19B |
| Gross Profit | 2.98B | 831.00M | 896.00M | 757.00M | 9.14B | 8.13B |
| EBITDA | 1.03B | 1.11B | 1.05B | 908.00M | 901.00M | 892.00M |
| Net Income | 174.00M | 237.00M | 144.00M | 176.00M | 210.00M | 276.00M |
Balance Sheet | ||||||
| Total Assets | 9.41B | 9.39B | 10.63B | 10.03B | 9.81B | 9.00B |
| Cash, Cash Equivalents and Short-Term Investments | 339.00M | 366.00M | 583.00M | 675.00M | 690.00M | 695.00M |
| Total Debt | 4.49B | 4.40B | 5.15B | 5.41B | 5.40B | 4.92B |
| Total Liabilities | 6.32B | 6.14B | 7.33B | 7.10B | 7.07B | 6.45B |
| Stockholders Equity | 3.09B | 3.12B | 3.16B | 2.89B | 2.74B | 2.55B |
Cash Flow | ||||||
| Free Cash Flow | 681.00M | 666.00M | 570.00M | 451.00M | 442.00M | 582.00M |
| Operating Cash Flow | 737.00M | 770.00M | 869.00M | 621.00M | 633.00M | 689.00M |
| Investing Cash Flow | -42.00M | 172.00M | -532.00M | -151.00M | -246.00M | -260.00M |
| Financing Cash Flow | -1.01B | -1.13B | -434.00M | -457.00M | -424.00M | -521.00M |
Humana AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | kr19.80B | 33.28 | 10.82% | 0.95% | 0.82% | 77.45% | |
71 Outperform | kr3.40B | 20.06 | 5.55% | 2.18% | -3.48% | -14.02% | |
68 Neutral | kr12.89B | 18.18 | 13.73% | 1.89% | 13.33% | 28.61% | |
67 Neutral | kr7.66B | 19.99 | 5.03% | 3.60% | -3.08% | -10.70% | |
65 Neutral | kr17.74B | 17.70 | ― | 0.82% | -1.07% | 81.76% | |
64 Neutral | kr36.78B | 39.03 | ― | 1.01% | 5.73% | 90.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:HUM
Humana AB
71.70
31.10
76.61%
SE:MCOV.B
Medicover AB
243.50
-21.73
-8.19%
SE:ATT
Attendo AB
117.90
50.49
74.89%
SE:ALIF.B
AddLife AB
162.30
-10.60
-6.13%
SE:ARJO.B
Arjo AB
28.38
-5.93
-17.30%
SE:AMBEA
Ambea AB
173.60
37.79
27.83%
Humana AB Corporate Events
Court of Appeal to Review Humana Assistans Damages Claim Against Swedish State
Aug 14, 2026
Humana Assistans AB, a subsidiary of Nordic care provider Humana, has secured leave to appeal a District Court ruling that rejected its damages claim against the Swedish state. The Court of Appeal’s decision means the substantive merits of H...
Humana boosts profitability and cash flow despite muted growth in Q2 2026
Jul 17, 2026
Humana AB reported modest top-line growth for the second quarter of 2026, with net revenue up 3 percent to SEK 2,581 million, while adjusted operating profit improved by 6 percent to SEK 81 million, reflecting better profitability in Sweden and Fi...
Humana to Present Q2 and First-Half 2026 Results on July 17
Jul 3, 2026
Humana has announced it will publish its interim report for the second quarter and first half of 2026 on July 17, with a telephone conference and webcast scheduled earlier that morning. The CEO and CFO will present the financial results and take q...
Humana AB Updates Share Capital After Redemption of Treasury Shares
Jun 30, 2026
Humana AB has completed a reduction of its outstanding share count after the Annual General Meeting approved the redemption of 3,786,664 treasury shares previously repurchased under earlier authorisations.Following this redemption and a related bo...
Humana Board Backs Ambea’s Premium Takeover Bid with Litigation Upside
Jun 29, 2026
Humana’s board has unanimously recommended that shareholders accept Ambea AB’s public takeover offer, which values Humana at SEK 62.30 per share in cash and shares, excluding any contingent value component. The offer represents premium...
Humana Finland Accelerates Organic Growth with SEK 270m Care Expansion Pipeline
Jun 26, 2026
Humana Finland, part of Nordic care group Humana, is sharpening its organic growth strategy by expanding its pipeline of new care units across all service areas, with a strong emphasis on disability services. The company is also upgrading its infr...
Humana Assistans Appeals Rejection of Damages Claim Over IVO Permit Decision
Jun 25, 2026
Humana Assistans AB, a subsidiary of Humana AB, will appeal a District Court ruling that rejected its damages claim against the Swedish state over the supervisory authority IVO’s earlier decision to revoke its permit. The company argues the ...
Humana denied damages over erroneous permit revocation
Jun 17, 2026
The Stockholm District Court has rejected a damages claim brought by Humana Assistans AB against the Swedish state over the Health and Social Care Inspectorate’s erroneous decision to revoke the company’s operating permit. The court fo...
Humana Ties SEK 2.3 Billion Credit Facility to Sustainability Targets
Jun 16, 2026
Humana AB has linked its SEK 2.3 billion revolving credit facility to key sustainability indicators, tying financing terms to customer satisfaction, employee engagement and reductions in Scope 1 and 2 climate emissions. The move embeds quality of ...
Humana Cancels 3.8 Million Treasury Shares While Keeping Share Capital Unchanged
Jun 15, 2026
Humana AB has completed a previously decided reduction of its share capital through the cancellation of 3,786,664 treasury shares, combined with a bonus issue that keeps total share capital unchanged at about SEK 1,279,656. Following registration ...
Humana AGM Approves Dividend, Share Issuance Mandate and Capital Changes
Jun 1, 2026
Humana AB’s Annual General Meeting approved the 2025 financial statements and confirmed a dividend of SEK 1.35 per share, with remaining earnings carried forward. Shareholders also granted discharge from liability to the board and CEO, re-el...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.